- Molecular NameChlorambucil
- SynonymChlocambucil; Chloraminophen; Chloraminophene; Chlorbutin; Chlorbutine; Chloroambucil; Chlorobutin; Chlorobutine; Phenylbutyric Acid Nitrogen Mustard
- Weight304.217
- Drugbank_IDDB00291
- ACS_NO305-03-3
- Show 3D model
- LogP (experiment)3.25
- LogP (predicted, AB/LogP v2.0)3.34
- pka5.8
- LogD (pH=7, predicted)1.29
- Solubility (experiment)12.4 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-1.65
- LogSw (predicted, AB/LogsW2.0)0.81
- Sw (mg/ml) (predicted, ACD/Labs)0.16
- No.of HBond Donors1
- No.of HBond Acceptors3
- No.of Rotatable Bonds9
- TPSA40.54
- StatusFDA approved
- AdministrationN/A
- PharmacologyA chemotherapy drug that has been mainly used in the treatment of chronic lymphocytic leukemia.
- Absorption_value100.0
- Absorption (description)Rapidly absorbed after oral administration with peak plasma concentrations being attained in 0.5 to 2 h.
- Caco_2N/A
- Bioavailability87.0
- Protein binding99.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic
- Half life1~2 h
- ExcretionIt is extensively metabolised; less than 1% of a dose is excreted in the urine unchanged. Phenylacetic acid mustard is a major metabolite.
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityThe most common side effect is bone marrow suppression. Other side effects include: gastrointestinal - nausea, vomiting, diarrhea, oral ulceration; central nervous system - tremors, muscular twitching, confusion, agitation, ataxia, flaccid paresis, hallucinations; dermatologic - urticaria, angioneurotic edema; miscellaneous - pulmonary fibrosis, hepatotoxicity and jaundice, drug fever, peripheral neuropathy, interstitial pneumonia, sterile cystitis, infertility, leukemia, and secondary malignancies.
- LD50 (rat)Letha dose against male Holtzman rats by intraperitoneal injection of the compound, dissolved in cottonseed oil; 3-6 animals/dose level, LD50=92
- LD50 (mouse)Lethal dose of the compound in mice upon intraperitoneal administration, LD50=49.54